Heather Eden
Family · Palm Bay, FLNPI 1093106650
Payments from drug & device makers
Across 202 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$812
- Sanofi$553
- GSK$458
- Novartis$451
- Genentech USA, Inc.$151
- plus $596 from 8 others
What the payments were for
- Food & beverage$4,05698%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,112 |
| Regeneron Healthcare Solutions, Inc. | 36 | $812 |
| Sanofi | 28 | $553 |
| GSK | 26 | $458 |
| Novartis | 26 | $451 |
| Genentech USA, Inc. | 2 | $151 |
| Optinose US, Inc. | 8 | $150 |
| Kaleo, Inc. | 7 | $122 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| Boehringer Ingelheim | 4 | $75 |
| Insmed, Inc. | 2 | $60 |
| Amgen | 3 | $57 |
| Phadia US Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $15 |
How this compares
$4,132 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $55,787 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $22,246 |
| Spiriva RespimatTiotropium Bromide | 25 | $21,879 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $19,020 |
| Epinephrine | 20 | $4,504 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,819 |
| Azelastine Hcl | 118 | $3,423 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,412 |
| Montelukast Sodium | 211 | $3,390 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 68 | $3,191 |
| Ipratropium Bromide | 39 | $2,333 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $2,008 |
| Fluticasone Propionate | 92 | $1,949 |
| Prednisone | 157 | $489 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 44 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $458 | $74,80788 claims |
| Boehringer IngelheimSpiriva Respimat | $75 | $21,87925 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $4,50420 claims |
| AstraZenecaSymbicort | $1,112 | $3,81911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Palm Bay
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.